Medicine summary -desvenlafaxine (to end January 2009)

			Case Group	Death Outcomes	Sole
Case Count			3	0	3
Reaction Count	General disorders and administration site conditions	Fatigue	1	0	1
		Drug ineffective	1	0	1
		General disorders and administration site conditions	2	0	2
	Investigations	Weight increased	1	0	1
		Investigations	1	0	1
	Metabolism and nutrition disorders	Decreased appetite	1	0	1
		Metabolism and nutrition disorders	1	0	1
	Nervous system disorders	Headache	1	0	1
		Amnesia	1	0	1
		Dysarthria	1	0	1
		Incoherent	1	0	1
		Nervous system disorders	4	0	4
	Psychiatric disorders	Anxiety	1	0	1
		Anger	1	0	1
		Insomnia	2	0	2
		Terminal insomnia	1	0	1
		Nightmare	1	0	1
		Suicidal ideation	2	0	2
		Psychiatric disorders	8	0	8
	Skin and subcutaneous tissue disorders	Hyperhidrosis	1	0	1
		Skin and subcutaneous tissue disorders	1	0	1
	Reaction		17	0	17